TrialJournal for immunotherapy of cancer2020

Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial.

Dmitriy Zamarin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.